UW-Madison spinoff company OnLume is continuing to develop its system for identifying tissue types during surgery. The company’s technology causes chemical labels to glow in the operating room.
If you take electric lighting for granted, you have not lived in the Democratic Republic of Congo, where lighting options often come down to kerosene, candles or flashlights. The company's solar lights are a new choice.
Electronic Theatre Controls, started in 1974 by four UW–Madison undergraduates, has built its success on a programmable electronic control for stage lighting.
Engineering Professor Jack Ma has more than 40 patents, more than 470 published papers and a half-dozen national professional fellowships.
A company started by a UW–Madison undergrad five years ago is finding success with an app that rewards grocery buyers who scan in their receipts.
The wearable system developed by Torq Labs is designed to help runners avoid injury by tracking leg movement with wireless sensors that transmit data to a smartphone app.
A UW–Madison spinoff company is refining a medical management software package designed to help doctors treat patients more efficiently.
Researchers are developing a "robust, simple and inexpensive way to increase the sensitivity of an existing TB test" by integrating a step very similar to a pregnancy test.
One of the most promising universal flu vaccines is being developed by FluGen, a spinoff from the University of Wisconsin–Madison. Next up is an experimental trial.
“We are uniquely positioned to help teams build apps with the same exact code that will work on the web, and on the App Store and Google Play,” Ionic CEO Max Lynch says.
The Accelerator Program represents a broadening of WARF’s original role, as it as recognized the need to guide and encourage start-up companies, and invest in them.
A new line of dairy-based snack bars developed to promote healthy eating and a healthy self-image among young women were created by a UW–Madison alumnus with help from UW–Madison’s Center for Dairy Research (CDR).
Igniter has helped in the creation of 17 startup companies based on UW–Madison discoveries over the past three years.
Carl Ross has more than 26 years of experience advancing a wide range of cell and gene therapies, vaccines and therapeutic proteins into human clinical trials.
“I spent three years getting D2P going, and we did some good things in commercializing innovation from campus,” John Biondi says. “Now it’s time to turn it over to someone else who can take it to the next level.”
Researchers at the University of Wisconsin–Madison have developed a new measurement for the volume and activity of beta cells, the source of the sugar-regulating hormone insulin.
Discovery to Product (D2P) staff have mentored UW–Madison students, staff and faculty towards successful technology commercialization, including patenting, partnership with industry, and new company formation.
A University of Wisconsin–Madison spinoff that makes an innovative material designed to speed healing of serious burns has begun a large clinical trial for the “regenerative skin tissue” it has been developing since 2000.